[1] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, 2021; 398, 957−80. doi:  10.1016/S0140-6736(21)01330-1
[2] Smolarek I, Wyszko E, Barciszewska AM, et al. Global DNA methylation changes in blood of patients with essential hypertension. Med Sci Monit, 2010; 16, Cr149−55.
[3] Wise IA, Charchar FJ. Epigenetic modifications in essential hypertension. Int J Mol Sci, 2016; 17, 451. doi:  10.3390/ijms17040451
[4] Dabravolski SA, Khotina VA, Sukhorukov VN, et al. The role of mitochondrial DNA mutations in cardiovascular diseases. Int J Mol Sci, 2022; 23, 952. doi:  10.3390/ijms23020952
[5] Stoccoro A, Coppede F. Mitochondrial DNA methylation and human diseases. Int J Mol Sci, 2021; 229, 4594. doi:  10.3390/ijms22094594
[6] El Haouari M, Rosado JA. Platelet function in hypertension. Blood Cells Mol Dis, 2009; 42, 38−43. doi:  10.1016/j.bcmd.2008.07.003
[7] Corsi S, Iodice S, Vigna L, et al. Platelet mitochondrial DNA methylation predicts future cardiovascular outcome in adults with overweight and obesity. Clin Epigenet, 2020; 12, 29. doi:  10.1186/s13148-020-00825-5
[8] Han LY, Liu YF, Duan SW, et al. DNA methylation and hypertension: emerging evidence and challenges. Brief Funct Genomics, 2016; 15, 460−9.
[9] Shaughnessy DT, McAllister K, Worth L, et al. Mitochondria, energetics, epigenetics, and cellular responses to stress. Environ Health Perspect, 2014; 122, 1271−8. doi:  10.1289/ehp.1408418
[10] Forte M, Stanzione R, Cotugno M, et al. Vascular ageing in hypertension: Focus on mitochondria. Mech Ageing Dev, 2020; 189, 111267. doi:  10.1016/j.mad.2020.111267